Usefulness of a slow-release tacrolimus for a patient with tacrolimus-induced renal injury after hemopoietic stem cell transplantation

DOI Web Site PubMed 5 References

Bibliographic Information

Other Title
  • 造血幹細胞移植後のタクロリムス起因性腎障害に対するタクロムス徐放製剤の有用性
  • ゾウケツ カン サイボウ イショク ゴ ノ タクロリムス キインセイジンショウガイ ニ タイスル タクロムスジョホウ セイザイ ノ ユウヨウセイ

Search this article

Abstract

In our facility, three patients developed tacrolimus (TAC)-induced renal dysfunction after allogeneic hemopoietic stem cell transplantation, although trough levels of TAC were within therapeutic ranges. They received an oral agent of slow-release TAC once a day instead of a regular form oral TAC twice a day. Following treatment with the prolonged-release agent, serum creatinine levels decreased and graft-versus-host disease (GVHD) did not occur. Use of this slow-release formulation may avoid toxic peak concentrations of TAC without the development of GVHD.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 53 (4), 469-471, 2012

    The Japanese Society of Hematology

References(5)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top